Purpose of Review: To apprise readers on recent updates in the clinical management of recurrent pregnancy loss (RPL) and review the role of reproductive immunology in RPL.Recent Findings: Topics discussed include the epidemiological and clinical definitions of RPL, a higher chromosomal abnormality rate in blastocysts from young patients with idiopathic RPL, and the role of uterine natural killer (uNK) cells in underlying reproductive immunopathology.Summary: Although clinically recognized pregnancy loss occurs in 15–25% of pregnancies, only 1–5% of losses can be attributed to RPL, a unique disorder defined as two or more failed clinical pregnancies. Despite a comprehensive evaluation, however, the etiology of 50% of RPL losses will remain unknown. Treatment of RPL focuses on addressing the underlying etiology: preimplantation genetic testing for structural rearrangement (PGT-SR) is recommended for patients with a balanced translocation, and preimplantation genetic testing for aneuploidy (PGT-A) has been shown to improve clinical pregnancy and live birth in patients with RPL. Recent studies promote the use of preconception low-dose aspirin at least 4 days a week, initiation of luteal start vaginal micronized progesterone, and treatment of occult chronic endometritis.